Abbisko Cayman Past Earnings Performance
Past criteria checks 0/6
Key information
3.6%
Earnings growth rate
88.8%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 23.4% |
| Return on equity | -21.8% |
| Net Margin | -2,264.3% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Abbisko Cayman makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 19 | -432 | 96 | 434 |
| 30 Sep 23 | 19 | -457 | 102 | 429 |
| 30 Jun 23 | 19 | -483 | 108 | 424 |
| 31 Mar 23 | 10 | -489 | 113 | 402 |
| 31 Dec 22 | 0 | -496 | 118 | 379 |
| 30 Sep 22 | 11 | -1,075 | 129 | 342 |
| 30 Jun 22 | 23 | -1,654 | 140 | 306 |
| 31 Mar 22 | 23 | -1,797 | 144 | 268 |
| 31 Dec 21 | 23 | -1,810 | 125 | 226 |
| 31 Mar 21 | 7 | -774 | 26 | 155 |
| 31 Dec 20 | 0 | -707 | 21 | 133 |
| 31 Dec 19 | 4 | -134 | 22 | 81 |
Quality Earnings: 2256 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2256 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare 2256's earnings growth over the past year to its 5-year average as it is currently unprofitable